EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets

Jasmine M Bacon, Johanna L Jones, Guei-Sheung Liu, Joanne L Dickinson, Kelsie Raspin iD

Cancer and Metastasis Reviews · 2024

DOI: 10.1007/s10555-024-10216-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, 2024. Verfasst von Jasmine M Bacon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia. Hauptthemen laut MEDLINE: Neoplasms, Ribosomal Proteins, Neoplasm Metastasis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: College of Health and Medicine, Select Foundation, Cancer Council Tasmania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mitochondrion is an essential cell organelle known as the powerhouse of the cell. Mitochondrial ribosomal proteins (MRPs) are nuclear encoded, synthesised in the cytoplasm but perform their main functions in the mitochondria, which includes translation, transcription, cell death and maintenance. However, MRPs have also been implicated in cancer, particularly advanced disease and metastasis across a broad range of cancer types, where they play a central role in cell survival and progression. For some, their altered expression has been investigated as potential prognostic markers, and/or therapeutic targets, which is the focus of this review. Several therapies targeting MRPs are currently approved by the Food and Drug Administration and the European Medicines Agency for use in other diseases, revealing the opportunity for repurposing their use in advanced and metastatic cancer. Herein, we review the evidence supporting key MRPs as molecular drivers of advanced disease in multiple cancer types. We also highlight promising avenues for future use of MRPs as precision targets in the treatment of late-stage cancers for which there are currently very limited effective treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsRibosomal ProteinsNeoplasm MetastasisHumansAnimalsPrognosisMitochondrial ProteinsMitochondriaMolecular Targeted TherapyBiomarkers, TumorAntineoplastic Agents

Stichwörter der Autor:innen

CancerMetastasisMitochondrial ribosomal proteinsPrognostic targetsTherapeutic targets

Substanzen

Ribosomal ProteinsMitochondrial ProteinsBiomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
  • Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.
  • Ophthalmology, Department of Surgery, University of Melbourne, East Melbourne, Victoria, Australia.
  • Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia. kelsie.raspin@utas.edu.au.

ORCID-Profile: Kelsie Raspin

Förderung

  • College of Health and Medicine
  • Select Foundation
  • Cancer Council Tasmania
  • University of Tasmania

Zitieren

APA

Bacon, J. M., Jones, J. L., Liu, G. S., Dickinson, J. L., & Raspin, K. (2024). Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-024-10216-4

Vancouver

Bacon JM, Jones JL, Liu GS, Dickinson JL, Raspin K. Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets. Cancer and Metastasis Reviews. 2024. doi:10.1007/s10555-024-10216-4

BibTeX
@article{Bacon2024,
  author = {Bacon, Jasmine M and Jones, Johanna L and Liu, Guei-Sheung and Dickinson, Joanne L and Raspin, Kelsie},
  title = {Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets},
  journal = {Cancer and Metastasis Reviews},
  year = {2024},
  doi = {10.1007/s10555-024-10216-4}
}
Kostenlos starten →